Abstract 5PSQ-076 Table 1
CharacteristicNivolumab plus Ipilimumab (n=11)Nivolumab (n=19)
Age, median (range), years 62 (44–74) 57 (37–83)
Male 6 (54.5) 16 (84.2)
Histology
Clear cell RCR 10 (90.9) 13 (68.4)
Papillary RCR 0 (0) 3 (15.8)
Not specified 1 (9.1) 3 (15.8)
ECOG (Eastern Cooperative Oncology Group) performance status
0 5 (45.5) 11 (57.9)
1 5 (45.5) 3 (15.8)
Not specified 1 (9.1) 5 (26.3)
Lung metastases 8 (72.7) 16 (84.2)
Liver metastases 2 (18.2) 6 (31.6)
NOTE: Data are No. (%).